Literature DB >> 30506093

[Classification and pathophysiology of angioedema].

T Buttgereit1, M Maurer2.   

Abstract

BACKGROUND: The classification of angioedema in daily clinical practice is often challenging.
OBJECTIVES: The goal is to review the most recent classification of angioedema and to discuss the underlying pathology.
MATERIALS AND METHODS: Current guidelines and research on the pathophysiology and classification of angioedema were evaluated.
RESULTS: Angioedema is mast cell mediator-induced or bradykinin-mediated. Classic examples for mast cell mediator-induced angioedema are acute angioedema due to allergic reactions or acute urticaria as well as recurrent angioedema in chronic urticaria. Bradykinin-mediated angioedema forms include hereditary angioedema and angiotensin converting enzyme (ACE) inhibitor-induced angioedema. Bradykinin-mediated angioedema is less common than mast cell mediator-induced angioedema and often more severe. The diagnostic workup of angioedema patients includes a good medical history and subsequent laboratory testing.
CONCLUSIONS: In most cases, mast cell mediator-induced and bradykinin-mediated forms of angioedema are readily classified clinically and/or by laboratory tests. In very rare cases, however, the cause and mediators of angioedema remain unknown.

Entities:  

Keywords:  Bradykinin; Differential diagnosis; Hereditary; Mast cell mediator; Urticaria

Mesh:

Substances:

Year:  2019        PMID: 30506093     DOI: 10.1007/s00105-018-4318-z

Source DB:  PubMed          Journal:  Hautarzt        ISSN: 0017-8470            Impact factor:   0.751


  26 in total

1.  Epidemiology of urticaria: a representative cross-sectional population survey.

Authors:  T Zuberbier; M Balke; M Worm; G Edenharter; M Maurer
Journal:  Clin Exp Dermatol       Date:  2010-12       Impact factor: 3.470

2.  Missense mutations in the coagulation factor XII (Hageman factor) gene in hereditary angioedema with normal C1 inhibitor.

Authors:  Georg Dewald; Konrad Bork
Journal:  Biochem Biophys Res Commun       Date:  2006-05-19       Impact factor: 3.575

3.  Comparative risk for angioedema associated with the use of drugs that target the renin-angiotensin-aldosterone system.

Authors:  Sengwee Toh; Marsha E Reichman; Monika Houstoun; Mary Ross Southworth; Xiao Ding; Adrian F Hernandez; Mark Levenson; Lingling Li; Carolyn McCloskey; Azadeh Shoaibi; Eileen Wu; Gwen Zornberg; Sean Hennessy
Journal:  Arch Intern Med       Date:  2012-11-12

4.  Chronic idiopathic urticaria: prevalence and clinical course.

Authors:  Kanokvalai Kulthanan; Sukhum Jiamton; Narumol Thumpimukvatana; Sumruay Pinkaew
Journal:  J Dermatol       Date:  2007-05       Impact factor: 4.005

5.  Symptom profile and risk factors of anaphylaxis in Central Europe.

Authors:  M Worm; G Edenharter; F Ruëff; K Scherer; C Pföhler; V Mahler; R Treudler; R Lang; K Nemat; A Koehli; B Niggemann; S Hompes
Journal:  Allergy       Date:  2012-02-16       Impact factor: 13.146

6.  Natural course of physical and chronic urticaria and angioedema in 220 patients.

Authors:  M M Kozel; J R Mekkes; P M Bossuyt; J D Bos
Journal:  J Am Acad Dermatol       Date:  2001-09       Impact factor: 11.527

Review 7.  Unmet clinical needs in chronic spontaneous urticaria. A GA²LEN task force report.

Authors:  M Maurer; K Weller; C Bindslev-Jensen; A Giménez-Arnau; P J Bousquet; J Bousquet; G W Canonica; M K Church; K V Godse; C E H Grattan; M W Greaves; M Hide; D Kalogeromitros; A P Kaplan; S S Saini; X J Zhu; T Zuberbier
Journal:  Allergy       Date:  2010-11-17       Impact factor: 13.146

Review 8.  Acquired C1-inhibitor deficiency and lymphoproliferative disorders: a tight relationship.

Authors:  Roberto Castelli; Andrea Zanichelli; Marco Cicardi; Massimo Cugno
Journal:  Crit Rev Oncol Hematol       Date:  2013-03-13       Impact factor: 6.312

9.  Clinical and laboratory parameters in predicting chronic urticaria duration: a prospective study of 139 patients.

Authors:  E Toubi; A Kessel; N Avshovich; E Bamberger; E Sabo; D Nusem; J Panasoff
Journal:  Allergy       Date:  2004-08       Impact factor: 13.146

10.  The definition and diagnostic testing of physical and cholinergic urticarias--EAACI/GA2LEN/EDF/UNEV consensus panel recommendations.

Authors:  M Magerl; E Borzova; A Giménez-Arnau; C E H Grattan; F Lawlor; P Mathelier-Fusade; M Metz; A Młynek; M Maurer
Journal:  Allergy       Date:  2009-09-30       Impact factor: 13.146

View more
  2 in total

1.  The international WAO/EAACI guideline for the management of hereditary angioedema - The 2021 revision and update.

Authors:  Marcus Maurer; Markus Magerl; Stephen Betschel; Werner Aberer; Ignacio J Ansotegui; Emel Aygören-Pürsün; Aleena Banerji; Noémi-Anna Bara; Isabelle Boccon-Gibod; Konrad Bork; Laurence Bouillet; Henrik Balle Boysen; Nicholas Brodszki; Paula J Busse; Anette Bygum; Teresa Caballero; Mauro Cancian; Anthony J Castaldo; Danny M Cohn; Dorottya Csuka; Henriette Farkas; Mark Gompels; Richard Gower; Anete S Grumach; Guillermo Guidos-Fogelbach; Michihiro Hide; Hye-Ryun Kang; Allen P Kaplan; Constance H Katelaris; Sorena Kiani-Alikhan; Wei-Te Lei; Richard F Lockey; Hilary Longhurst; William Lumry; Andrew MacGinnitie; Alejandro Malbran; Inmaculada Martinez Saguer; Juan José Matta Campos; Alexander Nast; Dinh Nguyen; Sandra A Nieto-Martinez; Ruby Pawankar; Jonathan Peter; Grzegorz Porebski; Nieves Prior; Avner Reshef; Marc Riedl; Bruce Ritchie; Farrukh Rafique Sheikh; William B Smith; Peter J Spaeth; Marcin Stobiecki; Elias Toubi; Lilian Agnes Varga; Karsten Weller; Andrea Zanichelli; Yuxiang Zhi; Bruce Zuraw; Timothy Craig
Journal:  World Allergy Organ J       Date:  2022-04-07       Impact factor: 5.516

Review 2.  Differences and Similarities in the Mechanisms and Clinical Expression of Bradykinin-Mediated vs. Mast Cell-Mediated Angioedema.

Authors:  Marcus Maurer; Markus Magerl
Journal:  Clin Rev Allergy Immunol       Date:  2021-02-03       Impact factor: 8.667

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.